Endocrine mucin-producing sweat gland carcinoma (EMPSGC) is a low-grade, indolent tumor found almost exclusively on the eyelids that may histologically mimic metastatic breast carcinoma. To our knowledge, we present the first case of EMPSGC located on the external ear, and the first case with histologic evidence of vascular and perineural invasion. Due to the aggressive potential of this lesion, wide local excision and adjuvant radiation therapy were performed to help reduce the risk of recurrence.

A 74-year-old woman with no prior history of cutaneous or internal malignancy presented to our dermatology department for a 2-week history of a growing lesion on her right tragus with associated numbness and tingling. Clinical exam revealed a 7-mm firm, pink to violaceous papule (Fig. 1). Shave biopsy showed nests of keratinocytes lacking peripheral palisading, suggestive of the surface of an adnexal neoplasm. The patient was referred for excision to better characterize the lesion. On surgical evaluation, the lesion was tender and felt fixed to the underlying tragus. It measured 2 cm at the greatest palpable dimension without associated lymphadenopathy.

Fig. 1.

A 7-mm firm, violaceous papule on the right tragus is shown.

Fig. 1.

A 7-mm firm, violaceous papule on the right tragus is shown.

Close modal

Pathology from incisional biopsy was consistent with an endocrine mucin-producing sweat gland carcinoma (EMPSGC), present at the deep margin. Of note, the patient had no history of breast cancer, and a normal mammogram the month before. Computed tomography of the neck did not show involvement of deeper structures or lymphadenopathy. She underwent excision with 1-cm margins as well as resection of the tragal cartilage. Pathology showed an infiltrative carcinoma with extensive vascular invasion, perineural invasion (PNI), and a focal associated mucinous carcinoma, with infiltrating carcinoma present at the deep margin (Fig. 2,Fig. 3). The tumor was immunoreactive for keratin 7, chromogranin, synaptophysin, androgen receptor, and estrogen receptor – an immunoprofile supportive of EMPSGC. She underwent re-excision of the right preauricular skin and additional medial tragal soft tissue and cartilage which showed residual carcinoma present adjacent to cartilage, all margins were negative for malignancy. Based on the indistinct margins of the tumor, deep invasion to cartilage, and perineural spread, a multidisciplinary team recommended adjuvant radiation. The patient received a total of 60 Gy of radiation in 30 fractions to the surgical site, ipsilateral parotid gland and neck (level 2/3 lymph nodes). She is being followed clinically every 3 months, with repeat imaging every 6 months. She has had no evidence of recurrence in an 18-month follow-up period since completing her radiation treatments.

Fig. 2.

An infiltrative carcinoma with cribriform architecture and associated mucinous component is noted (100×). Vascular invasion is noted in the upper right-hand corner (arrow, 400×) and shown at higher magnification in the inset.

Fig. 2.

An infiltrative carcinoma with cribriform architecture and associated mucinous component is noted (100×). Vascular invasion is noted in the upper right-hand corner (arrow, 400×) and shown at higher magnification in the inset.

Close modal
Fig. 3.

Perineural invasion is seen in the lower right-hand corner (400×).

Fig. 3.

Perineural invasion is seen in the lower right-hand corner (400×).

Close modal

EMPSGC is a rare, slow-growing tumor that generally presents as a solitary, asymptomatic nodule on the eyelid of elderly individuals [1, 2]. Local recurrence may occur following surgical excision [3]; however, there have been no reported cases of lymph node involvement or distant metastases.

EMPSGC is a primary skin tumor characterized by well-defined nodules of uniform polygonal epithelial cells with bland nuclei [3]. Several studies have demonstrated that EMPSGC may be a precursor lesion to invasive mucinous carcinoma in the skin given synchronous presentations [1]. As this tumor is morphologically similar to endocrine ductal carcinoma in situ of the breast, metastatic breast cancer should be considered in the differential diagnosis [1, 3].

Prior reports of EMPSGC with or without invasive mucinous carcinoma describe an indolent tumor that lacks vascular invasion or PNI. PNI and lymphovascular invasion have been documented in other sweat gland tumors, which can behave aggressively, and be more likely to recur or metastasize [4, 5]. Treatment for EMPSGC typically consists of tumor extirpation via wide local excision or Mohs surgery [1, 2]. Due to high-risk histologic features and deep extension of this preauricular tumor, the patient was treated with wide local excision followed by adjuvant radiation to reduce the risk of recurrence and treat the at-risk regional lymph nodes. While this treatment has not been reported in EMPSGC, surgery followed by adjuvant radiation in adnexal tumors of the head and neck with high-risk features has shown promise to improve locoregional control [5].

This study is a case report and does not include identifiable photographs or any patient identifiers. The manuscript was prepared in compliance with all ethical and confidentiality guidelines and principles.

The authors have no relevant conflicts of interest to declare.

The authors did not receive any funding for this study.

Neera R. Nathan made substantial contributions to the acquisition, analysis, and interpretation of data for the work, drafted the work, approved the final version, and agrees to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Mai P. Hoang made substantial contributions to the analysis and interpretation of data for the work, revised the work for important intellectual content, approved the final version, and agrees to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Kevin S. Emerick, Gideon P. Smith, and Molly Yancovitz made substantial contributions to the acquisition, analysis, and interpretation of data for the work, revised the work for important intellectual content, approved the final version, and agrees to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

1.
Zembowicz
A
,
Garcia
CF
,
Tannous
ZS
,
Mihm
MC
,
Koerner
F
,
Pilch
BZ
.
Endocrine mucin-producing sweat gland carcinoma: twelve new cases suggest that it is a precursor of some invasive mucinous carcinomas
.
Am J Surg Pathol
.
2005
Oct
;
29
(
10
):
1330
9
.
[PubMed]
0147-5185
2.
Scott
BL
,
Anyanwu
CO
,
Vandergriff
T
,
Nijhawan
RI
.
Endocrine Mucin-Producing Sweat Gland Carcinoma Treated With Mohs Micrographic Surgery
.
Dermatol Surg
.
2017
Dec
;
43
(
12
):
1498
500
.
[PubMed]
1076-0512
3.
Flieder
A
,
Koerner
FC
,
Pilch
BZ
,
Maluf
HM
.
Endocrine mucin-producing sweat gland carcinoma: a cutaneous neoplasm analogous to solid papillary carcinoma of breast
.
Am J Surg Pathol
.
1997
Dec
;
21
(
12
):
1501
6
.
[PubMed]
0147-5185
4.
Cardoso
JC
,
Calonje
E
.
Malignant sweat gland tumours: an update
.
Histopathology
.
2015
Nov
;
67
(
5
):
589
606
.
[PubMed]
0309-0167
5.
Wang
LS
,
Handorf
EA
,
Wu
H
,
Liu
JC
,
Perlis
CS
,
Galloway
TJ
.
Surgery and Adjuvant Radiation for High-risk Skin Adnexal Carcinoma of the Head and Neck
.
Am J Clin Oncol
.
2017
Aug
;
40
(
4
):
429
32
.
[PubMed]
0277-3732
Open Access License / Drug Dosage / Disclaimer
This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND). Usage and distribution for commercial purposes as well as any distribution of modified material requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.